PRESS RELEASE published on 05/19/2025 at 07:51, 1 year 5 months ago AB Science reçoit un brevet chinois protégeant le masitinib dans le traitement du Covid-19 jusqu’en 2041, ajoutant ainsi une indication supplémentaire bénéficiant d’une protection à long terme de la propriété intellectuelle AB Science reçoit un brevet chinois pour le masitinib dans le traitement du COVID-19 jusqu'en 2041, renforçant sa protection en propriété intellectuelle COVID-19 Propriété Intellectuelle AB Science Masitinib Brevet Chinois
PRESS RELEASE published on 05/19/2025 at 07:51, 1 year 5 months ago AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection AB Science receives Chinese patent protecting masitinib in the treatment of COVID-19 until 2041, providing long-term intellectual property protection. Collaboration with University of Chicago for COVID-19 research Intellectual Property COVID-19 Treatment AB Science Masitinib Chinese Patent
BRIEF published on 05/01/2025 at 10:11, 1 year 5 months ago AB Science reporte la publication de son rapport financier annuel 2024 Euronext Paris Rapport Financier Publication Retardée AB Science Masitinib
BRIEF published on 05/01/2025 at 10:11, 1 year 5 months ago AB Science postpones the publication of its 2024 annual financial report Euronext Paris Financial Report Publication Delayed AB Science Masitinib
PRESS RELEASE published on 05/01/2025 at 10:06, 1 year 5 months ago AB Science publiera son rapport financier annuel 2024 le vendredi 9 mai 2025 AB Science annonce le report de la publication de son rapport financier annuel 2024 au 9 mai 2025 pour achever l'audit. La société se spécialise dans les inhibiteurs de protéines kinases Rapport Financier Audit AB Science Masitinib Inhibiteurs De Protéines Kinases
PRESS RELEASE published on 05/01/2025 at 10:06, 1 year 5 months ago AB Science will publish its 2024 annual financial report on May 9, 2025 AB Science postpones the publication of its 2024 annual financial report to May 9, 2025, to allow auditors more time for audit work. The report will be released after trading hours Financial Report Postponement Auditors AB Science 2024 Annual Report
BRIEF published on 04/23/2025 at 19:04, 1 year 6 months ago EMA Grants Orphan Drug Status to AB8939 for AML Treatment AB Science AB8939 EMA Approval Acute Myeloid Leukemia Orphan Designation
BRIEF published on 04/23/2025 at 19:04, 1 year 6 months ago L'EMA accorde le statut de médicament orphelin à AB8939 pour le traitement de la LAM AB Science AB8939 Approbation De L'EMA Leucémie Myéloïde Aiguë Désignation D'orphelin
PRESS RELEASE published on 04/23/2025 at 18:59, 1 year 6 months ago AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia AB Science's AB8939 granted orphan drug designation by EMA in EU for treating acute myeloid leukemia, showing significant benefit over current therapies. Preclinical data reveals efficacy and safety Orphan Drug Designation AB Science EMA AB8939 Acute Myeloid Leukemia
PRESS RELEASE published on 04/23/2025 at 18:59, 1 year 6 months ago La molécule AB8939 obtient la désignation de médicament orphelin auprès de l'EMA dans le traitement de la leucémie myéloïde aigue La molécule AB8939 obtient la désignation de médicament orphelin dans l'Union Européenne pour le traitement de la leucémie myéloïde aigüe. AB Science fait un pas important dans le domaine de la recherche médicale Traitement AB Science Médicament Orphelin AB8939 Leucémie Myéloïde Aiguë
Published on 10/29/2026 at 13:31, 1 hour 13 minutes ago First Breach Advances Ammunition and Drone Manufacturing Expansion as U.S. Reshoring Accelerates
Published on 10/29/2026 at 13:00, 1 hour 44 minutes ago NuRAN Wireless Secures US$10 Million Non-Dilutive Facility and Confirms No ATM Sales at Current Market Levels
Published on 10/29/2026 at 13:00, 1 hour 44 minutes ago Core Silver Unveils Multiple New Broad Copper-Bearing VMS Intercepts at the Touleary Discovery Zone
Published on 10/29/2026 at 12:35, 2 hours 9 minutes ago ESGold Advances Historic Mine Waste Reclamation With MOU for Up to 300,000 Tonnes of Aggregate Annually
Published on 10/29/2026 at 12:30, 2 hours 14 minutes ago AIML Subsidiary NeuralCloud Signs Agreement with Etisense to Advance Animal-Model ECG Labeling with MaxYield(TM)
Published on 10/29/2026 at 14:13, 31 minutes ago Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy
Published on 10/29/2026 at 14:00, 44 minutes ago Ringmetall acquires Rapak and enters the North American bag-in-box market
Published on 10/29/2026 at 14:00, 44 minutes ago SGL Carbon and X-energy sign further supply contract
Published on 10/29/2026 at 07:20, 7 hours 24 minutes ago Q3 2026: Air Liquide accelerates, driven by sales growth and the launch of its strategic plan
Published on 10/29/2026 at 07:20, 7 hours 24 minutes ago T3 2026 : Air Liquide accélère, porté par des ventes en croissance et le lancement de son plan stratégique